Sun Pharma is recalling approximately 55,000 bottles of a generic medication used to treat bowel disease in the US market. The recall is due to "Failed Dissolution Specifications," according to the US Food & Drug Administration (USFDA). The affected Mesalamine extended-release capsules were manufactured at Sun Pharma's Mohali plant and distributed in the US by Sun Pharmaceutical Industries Inc. Mesalamine capsules are indicated for treating mild to moderate ulcerative colitis. The US generic drug market was valued at around USD 115.2 billion in 2019, with Sun Pharma being a major player in the market.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.